Novo Nordisk (NYSE: NVO) details progress on DKK 15B share buyback

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its B share repurchase programme. The company plans to repurchase up to DKK 15 billion of B shares over 12 months beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 from 6 May 2026 to 1 February 2027.

As of 26 June 2026, Novo Nordisk has repurchased 22,009,179 B shares since 4 February 2026 at an average price of DKK 268.02 per share, for a total of DKK 5,898,848,910. Under the sub-programme initiated 6 May 2026, 7,250,000 B shares have been repurchased for DKK 2,098,848,921.

Following these transactions, Novo Nordisk holds 39,194,480 B shares of DKK 0.10 as treasury shares, equal to 0.9% of its share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000.

Key Figures

Overall buyback size: DKK 15 billion Sub-programme limit: DKK 11,200,000,010.45 Total shares repurchased: 22,009,179 B shares +5 more

8 metrics

Overall buyback size DKK 15 billion Planned B share repurchases over 12 months from 4 February 2026

Sub-programme limit DKK 11,200,000,010.45 B share repurchases from 6 May 2026 to 1 February 2027

Total shares repurchased 22,009,179 B shares Repurchased since 4 February 2026 as of 26 June 2026

Total buyback value DKK 5,898,848,910 Value of 22,009,179 B shares repurchased since 4 February 2026

Average repurchase price DKK 268.02 per B share Average price paid since 4 February 2026

Treasury B shares 39,194,480 B shares Treasury holding after reported transactions, equal to 0.9% of share capital

Total share capital 4,465,000,000 shares Total A and B shares including treasury shares

Programme-to-date under sub-programme 7,250,000 B shares; DKK 2,098,848,921 Accumulated under programme initiated 6 May 2026

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, foreign private issuer, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 39,194,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Regulation No 596/2014 regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/29/2026 - 04:16 PM Accepted by SEC EDGAR 06/29/2026 - 04:16 PM Learn about SEC filing dates

FAQ

What share buyback programme did Novo Nordisk (NVO) update in this 6-K?

Novo Nordisk updated its B share repurchase programme of up to DKK 15 billion over 12 months starting 4 February 2026. This includes a specific sub-programme initiated 6 May 2026 under European Safe Harbour Rules.

How much stock has Novo Nordisk (NVO) repurchased so far in 2026?

As of 26 June 2026, Novo Nordisk has repurchased 22,009,179 B shares since 4 February 2026. The average price paid was DKK 268.02 per B share, for a total transaction value of DKK 5,898,848,910.

What are the details of Novo Nordisk’s current B share sub-programme?

Under the sub-programme started 6 May 2026, Novo Nordisk may repurchase B shares for up to DKK 11,200,000,010.45. The period runs from 6 May 2026 to 1 February 2027 and operates under EU Safe Harbour Rules for share buybacks.

How many shares has Novo Nordisk bought under the May 2026 sub-programme?

Under the share repurchase sub-programme initiated 6 May 2026, Novo Nordisk has repurchased 7,250,000 B shares. These purchases represent a total transaction value of DKK 2,098,848,921 based on the reported individual daily buybacks.

What is Novo Nordisk’s current level of treasury shares and share capital?

Novo Nordisk now holds 39,194,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of its share capital. The total number of A and B shares outstanding, including treasury shares, is 4,465,000,000.

Over what period will Novo Nordisk’s DKK 15 billion buyback run?

The overall B share repurchase programme of up to DKK 15 billion runs over a 12‑month period beginning 4 February 2026. Within this, a separate sub-programme operates from 6 May 2026 to 1 February 2027 under EU Safe Harbour Rules.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

June 29, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 29 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 22 June 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	6,200,000		1,777,005,178
22 June 2026	220,000	291.32	64,091,259
23 June 2026	210,000	306.05	64,269,567
24 June 2026	210,000	309.81	65,060,127
25 June 2026	210,000	314.91	66,131,566
26 June 2026	200,000	311.46	62,291,224
Accumulated under the programme	7,250,000		2,098,848,921

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 39,194,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 26 June 2026, Novo Nordisk has since 4 February 2026 repurchased a total 22,009,179 B shares at an average share price of DKK 268.02 per B share equal to a transaction value of DKK 5,898,848,910.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
globalmedia@novonordisk.com		lzsk@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Ida Schaap Melvold		Sina Meyer
+45 3077 5649		+45 3079 6656
idmg@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 3444 2613		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 40/ 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 29, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer